However, if the FDA removes a drug from its shortage list, these compounded versions are no longer allowed to be sold. Compounded drugs are not approved by the FDA. Why Did the FDA Change Its Stance?

The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug Mountjaro has been on the list since 2022 and weight-loss drug Zepbound was ...

If there's a diet ... drugs are in short supply enabled thousands, or even millions, of people to access costly GLP-1 ...

“This drug takes the first new approach to schizophrenia treatment in decades,” Tiffany Farchione, director of FDA’s division ... wouldn’t pay the list price. The approval of Cobenfy ...

The US Food and Drug Administration ... approved by the FDA, and it is expected to become available in the first half of 2025. Stelara, manufactured by Johnson & Johnson, has a list price of ...

While many people think attaining healthy weight loss is as easy as eating a balanced diet and engaging in regular physical ...

2, 2024 — The FDA has approved Regeneron and Sanofi’s drug Dupixent for patients with ... COPD-related changes in the lungs. Dupixent’s list of indications already include asthma, eczema ...

The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders ...

The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and diabetes drug from its official shortage list and allow compounding ...

If there’s a diet, Janet McCaskill says ... worried could create safety issues because compounded drugs are not FDA-approved. But for people like McCaskill, it’s been a lifeline.

the next step will be for the FDA to propose adding bemotrizinol to the list of over-the-counter drugs that are "generally recognized as safe and effective" to be sold to Americans. The public ...